-

Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a company developing next generation therapeutic antibodies, announced today that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic. The preclinical research findings will be presented at the 13th Annual World Bispecific Summit, Thursday, September 22nd, 2022 and at the Immuno-Oncology Summit, Wednesday, October 12th, 2022, both in Boston.

The presentation will highlight preclinical data related to the lead candidate INV322, a SNIPER™ Bispecific Antibody co-targeting CTLA-4 and CD25. In vitro studies have characterized avidity-mediated binding of INV322 to these tumor Treg antigens as well as an antibody dependent cell cytotoxicity (ADCC) mediated mode of action. In vivo studies using a murine surrogate also show potent anti-tumor responses after a single dose and selective regulatory T cell (Treg) depletion in syngeneic mice. Moreover, synergistic anti-tumor activity was also observed in combinations with anti-PD-1 and anti-PD-L1 agents.

“We are very pleased with the strong preclinical data that our research team has generated with INV322 using our proprietary multispecific B-Body® Platform. INV322 also appears well tolerated in ongoing toxicology studies and thus we are also encouraged by its therapeutic potential as we progress our IND-enabling activities,” said Pereira. “These efforts are also providing validation for both the SNIPER Bispecific antibody therapeutics approach, and our robust multispecific B-Body Platform.”

Jonathan Davis, Ph.D., Invenra VP of Innovation and Strategy, will also be presenting on the Invenra B-Body Platform at the 13th Annual World Bispecific Summit. "Our platform has binding, biophysical, and manufacturing properties equivalent to the best conventional monoclonal antibodies, and far superior to the typical bispecific antibody platform,” said Davis. “We are very excited to see the B-Body Platform and SNIPER Bispecific antibodies advancing in multiple indications and believe this will be a pivotal platform for bispecific antibody therapeutics."

About INV322

INV322 is a next generation anti-CTLA-4 x CD25 bispecific mAb developed using Invenra’s high-developability B-Body Platform. Using the SNIPER Bispecific approach, the antibody was designed with optimized affinities for both antigens, permitting avid antibody binding specifically when both antigens are present. The antibody was also optimized for an ADCC-mediated MOA and has exhibited excellent developability properties at scale.

About Invenra Inc.

With a vision to cure cancer and other immune-related diseases, Invenra is redefining what is possible by harnessing the human immune response and creatively optimizing therapies to eradicate even the most challenging of therapeutic targets. Since our founding, we have developed an extensive and proprietary set of biological tools that have enabled us to design and develop bi- and multi-specific antibody candidates with novel mechanisms of action that have demonstrated best-in-class activity in preclinical studies to date. The foundation of our innovation is our B-Body® Platform, which enables versatile antibody constructs designed for improved expression, purification, stability, and binding of a wide variety of potential cargo to our human IgG-like scaffolds. Building off this foundation, we have developed a fully integrated candidate discovery platform that has already delivered multiple preclinical candidates for us and our partners. For more information, please visit Invenra.com.

Contacts

Mark McCormick
Director of Marketing and Communications
Invenra Inc.
+1 (608) 286-2642
media@invenra.com

Invenra Inc.


Release Versions

Contacts

Mark McCormick
Director of Marketing and Communications
Invenra Inc.
+1 (608) 286-2642
media@invenra.com

More News From Invenra Inc.

Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics

MADISON, Wis.--(BUSINESS WIRE)--Orion Corporation (“Orion”), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body® platform. Under the terms of the agreements, Invenra will leverage its B-Body® bispecific antibody platform from monoclonal antibody discovery to...

Invenra Unveils Rapid Bispecific Antibody Discovery Services – 4 Months from Start to Finish

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined service can identify bispecific antibody lead panel candidates in as little as four months. With these accelerated services, Invenra continues to build on its reputation for groundbreaking, client-focused discovery models. Recognizing the critical need for faster timelines in preclinical antibody disc...

Invenra Welcomes Three Industry Leaders to Its Board of Directors

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the addition of three distinguished professionals to its Board of Directors: Saira Ramasastry, Heather Preston, MD, and William Hinshaw. Together, these leaders bring decades of expertise in life sciences, encompassing clinical development, biotherapeutic commercialization, and strategic growth within the biotechnology industry. Saira Ramasastry has over 25 years of experience in the life sciences, successfully building compani...
Back to Newsroom